Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics, Inc. (NYSE American: TOVX) is a clinical-stage company whose news flow centers on the development of therapeutics for cancer and related diseases. The company regularly issues updates on its lead oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec), including clinical trial results, regulatory interactions, and presentations at major medical congresses.
Investors following TOVX news can expect coverage of data from the VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, where Theriva has reported improved overall survival, progression free survival, and duration of response for patients treated with VCN-01 plus gemcitabine/nab-paclitaxel compared with standard-of-care alone. News also highlights regulatory milestones such as scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a proposed Phase 3 trial, and company plans to discuss pivotal trial protocols with regulators.
Theriva’s releases also describe progress in retinoblastoma, including Phase 1 safety and clinical outcome data for intravitreal VCN-01 in refractory pediatric patients, as well as preclinical developments from the VCN-X discovery program, such as VCN-12. Beyond oncology, news items cover SYN-004 (ribaxamase) data in allogeneic hematopoietic cell transplant recipients and its potential role in protecting the gut microbiome and reducing acute graft-versus-host disease.
Additional TOVX news includes quarterly operational and financial updates, public offerings and warrant transactions, at-the-market equity programs, and proxy-related matters tied to share issuance approvals. This page aggregates these disclosures so readers can review Theriva’s clinical, regulatory, and financing developments in one place and track how its pipeline and capital strategy evolve over time.
Theriva Biologics (TOVX) reported positive safety and pharmacokinetic data from its Phase 1b/2a trial of SYN-004 (ribaxamase) at the 2023 Tandem Meetings. The ongoing trial focuses on HCT patients to prevent acute graft-versus-host disease. Preliminary findings show that SYN-004 is well-tolerated, with no serious adverse events linked to the drug. The trial is evaluating different beta-lactam antibiotics and aims to enroll up to 36 participants. The company plans further studies to assess SYN-004's potential benefits for patients with hematologic cancers.
Theriva Biologics (NYSE American: TOVX) announced its participation in the B. Riley Securities 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The Company will provide a corporate update and hold one-on-one investor meetings. The presentation is set for January 19, 2023, at 1:30 PM ET. Theriva specializes in developing therapeutics for cancer and related diseases, focusing on high unmet medical needs. Their key candidates include VCN-01, SYN-004, and SYN-020, aimed at enhancing cancer treatment efficacy and improving patient outcomes. For more details, visit their website.
Theriva Biologics (NYSE American: TOVX) announced the initiation of its Phase 2b trial, VIRAGE, for the treatment of newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). The first patient has been dosed in Spain, with a total enrollment of 92 adults planned across the US, Spain, and Germany. The trial will evaluate the safety and efficacy of VCN-01 combined with standard chemotherapy (gemcitabine/nab-paclitaxel). Primary endpoints include overall survival and safety, with additional metrics assessing progression-free survival and immune response. This trial represents a vital step towards improving treatment for patients with high unmet needs in oncology.
Theriva Biologics (NYSE American: TOVX) announced the dosing of the first patient in a Phase 1 clinical trial of VCN-01, an oncolytic adenovirus, targeted at treating high-grade brain tumors. Conducted at St. James’s University Hospital in collaboration with the University of Leeds, this trial aims to assess the safety and effectiveness of VCN-01 in patients scheduled for surgical resection. Successful results could significantly improve treatment options for patients with challenging brain tumors, reducing the need for invasive surgeries.
Theriva Biologics (NYSE American: TOVX) has announced participation in two investor conferences in December 2022. The first is the Alliance Global Partners Virtual Series on December 7, featuring a fireside chat and one-on-one meetings at 11:00 AM ET. The second is the Sidoti Virtual Conference on December 8, offering a corporate update at 9:15 AM ET. Webcasts for both events can be accessed via the company’s website. Theriva focuses on developing therapeutics for cancer and related diseases, utilizing innovative platforms including oncolytic adenoviruses.
Theriva Biologics (TOVX) announced positive clinical data and received FDA clearance for its Phase 2 trial of VCN-01 for pancreatic cancer. In Q3 2022, its cash reserves stood at $50.5 million, expected to fund operations into Q1 2024. The company also reported a 30% increase in R&D expenses to $2.6 million, linked to VCN-01 initiatives. Additionally, SYN-004 (ribaxamase) showed promising safety data, with patient enrollment in Cohort 2 commenced. A conference call is scheduled for November 11 to discuss these updates and financial results.
Theriva Biologics (NYSE American: TOVX) has rescheduled its conference call to November 11, 2022, at 8:30 a.m. ET to discuss Q3 2022 financial results and corporate updates. The original date was set for November 10. Participants can join via phone or access the call through the company's website. Theriva is focused on developing therapeutics for cancer treatment, with key products including VCN-01, SYN-004, and SYN-020, aimed at improving patient outcomes in high unmet need areas.
Theriva Biologics (TOVX) will host a conference call on November 10, 2022, at 8:30 a.m. ET, to discuss its financial results for Q3 2022, ending September 30. The call will provide a corporate update, with live participation available via phone or online. The company specializes in developing therapeutics for cancer and related diseases, including innovative treatments like VCN-01, SYN-004, and SYN-020. For further details, visit their website.
Theriva Biologics (TOVX) announced the dosing of the first patient in Cohort 2 of its ongoing Phase 1b/2a clinical trial for SYN-004, aimed at preventing acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Following a positive safety review of Cohort 1 by an independent committee, the trial will assess SYN-004’s safety and pharmacokinetics while evaluating its protective effects on the gut microbiome. The trial is expected to enroll up to 36 participants, advancing therapeutic options for patients with hematologic cancers.
Theriva Biologics (NYSE American: TOVX) announced a KOL webinar on November 7, 2022, at 11 a.m. ET, featuring experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D. The discussion will focus on the oncolytic virus landscape and data supporting the Company’s novel oncolytic adenovirus platform for treating cancers with high unmet needs, specifically pancreatic ductal adenocarcinoma (PDAC). The upcoming Phase 2 trial, VIRAGE, will evaluate VCN-01 combined with standard chemotherapy. A live Q&A will follow the presentation.